Tinea Pedis Treatment Market
Global Industry Analysis (2018 – 2021) – Growth Trends and Market Forecast (2022 – 2026)
All interactions and sensitive information remain confidential.
Custom Research Service
Undertaking exclusive research tailored for your business.
Rising Prevalence of Bacterial, and Fungal Infections Fuels Demand for Tinea Pedis Treatment
Tinea pedis (athlete’s foot), a type of foot infection caused by a dermatophyte fungus, is particularly prevalent in hot, and tropical environments. Trichophyton (T.) rubrum, T. interdigitale, and Epidermophyton floccosum are the most common dermatophyte fungi causing tinea pedis. The infection may be accompanied by other fungal infections, viz. tinea manuum, tinea cruris, or tinea unguium. Tinea pedis occurs as any of the four clinical forms, or in combination - chronic hyperkeratotic, chronic intertriginous, acute ulcerative, and vesiculobullous. Males, and adolescents are, typically, prominently afflicted by tinea pedis but the infection can also affect females, children, and elderly people.
The causative organism is mostly attracted by walking barefoot in a public change room, or using a shared towel that may transmit the infection. The increasing rate of incidence of fungal, and bacterial infectious diseases is predominantly driving the growth of the tinea pedis treatment market. The demand for tinea pedis treatment is further fostered by a growing number of immunocompromised patients worldwide. The market is expected to gather pace as the focus zooms in on R&D of better, effective treatments. The regulatory requisites for treatment approvals, however, are still a challenge facing companies in the global tinea pedis treatment market. Consistently growing geriatric population is another key factor supporting the market growth.
Aggressive Clinical Representation of Interdigital Tinea Pedis to Augment Demand for Tinea Pedis Treatment
Research estimates the prevalence of tinea pedis to be between 3-10% depending on climatic conditions in different parts of the world. There are highly surprising numbers (~70% of people across the globe are likely to develop athlete’s foot at some point) also available through some of the literature published in public domain. Tinea pedis mainly occurs in interdigital spaces. The occurrence of interdigital tinea pedis is higher than other types of tinea pedis. Interdigital tinea pedis is the most common form that is caused by T. rubrum and occurs in the fourth and fifth toe web spaces, and sometimes, aggravated to the entire foot. This has led to an increased focus on the treatment of interdigital tinea pedis. Other types include plantar tinea pedis, and vesicular tinea pedis. Besides, convenient access through over-the-counter (OTC) treatment for the athlete’s foot, affordable drug options, and new product developments are likely to boost the growth of the tinea pedis treatment market during the forecast period.
Growing Demand for Combination Therapies, Coupled with a Strong Product Pipeline, Upholds Tinea Pedis Treatment Market
The combination therapy is recognised as a prominent treatment option, which has gained traction over the recent past. It combines the systemic, and topical treatments to gain higher efficacy, and gives faster results. It particularly helps in avoiding the re-occurrence of the disease. For example, the combination of topical terbinafine, 10% urea ointment, and oral terbinafine has been considered to be the most efficient method for treating tinea pedis. Moreover, there have been multiple promising topical drug agents that are currently in the various developmental stages of the pipeline. These drugs supposedly possess a superior safety and efficacy profile. Novan, Inc. is developing SB208, a nitric oxide-releasing topical drug candidate. Its development for the treatment of fungal infections of the skin, and nails is underway and it has already showcased positive outcomes in its clinical trial phase 1.
Topical Antifungals Rule Tinea Pedis Treatment Market
The most preferred, and perceived as the safest tinea pedis treatment available is that of topical antifungals. While antifungals are first line of treatment used for athlete’s foot, the most commonly used antifungal drugs include clotrimazole, ketoconazole, econazole, terbinafine, miconazole, itraconazole, griseofulvin, terbinafine, and sulconazole. The recurrence is common, and the treatment must often be prolonged. In case of recurrence, and moisture development, oral antifungals, and drying agents are often used as a second line of treatment. Commonly recommended drying agents include antifungal powders (e.g., miconazole), Burow solution (5% aluminum subacetate), gentian violet, and 20-25% aluminum chloride solution. Oral antifungals are typically preferred for a long-term response in case of medium to severe cases. However, low efficacy of the current treatment regimen is a longstanding challenge to the expansion of tinea pedis treatment market.
North America, and Europe are Prominent Regions
The US, and the countries in Europe are dominating the global tinea pedis treatment market. As per Diabates.org, in 2018, roughly 34 million diabetic US citizens remained undiagnosed, which points to a significant risk holding population in the US alone. On the other hand, the increasing elderly population in Europe is also contributing to the increasing demand for tinea pedis treatment within the region. Moreover, people from these regions are more cautious about their physical appearance, and grooming, which is also a factor driving the demand for tinea pedis.
Key Market Players Prioritise Collaborative Activities to Strengthen Market Positioning
Alva-Amco Pharmacal Companies, Inc., Novan Inc., Aurobindo Pharma Limited, Mylan N.V, Cipla Ltd., GlaxoSmithKline plc, Johnson & Johnson; Novartis AG, Merck & Co. Inc., ProFoot, Inc., Qilu Pharmaceutical Co. Ltd., Taisho Pharmaceutical Co. Ltd., Taro Pharmaceutical Industries Ltd., Sun Pharmaceuticals Limited, Bayer AG, Breckenridge Pharmaceutical, Inc., and Perrigo Company are some of the prominent companies steering the competition in the global tinea pedis treatment market.
Key market players are actively seeking collaboration opportunities to enhance their global market positioning, and achieve greater market penetration. Recently in August 2020, Teva Pharmaceuticals entered a collaboration with Douglas Pharmaceuticals America Ltd., Novum Pharmaceutical Research Services, and ACM Global Laboratories to observe the potential effectiveness of KETOCONAZOLE cream for treating tinea pedis. Earlier in November 2018, Sun Pharmaceuticals Ltd. has brought a Japanese Drug maker Polo Pharma which is engaged in manufacturing, sales, and distribution of branded, and generic products - particularly in dermatology.